Category: united states

Amid controversial Sarepta approval decision, FDA head calls for key study retraction

FDAThe head of the U.S. Food and Drug Administration (FDA) has called for the retraction of a study about a drug that the agency itself approved earlier this week, despite senior staff opposing the approval.

On September 19, the FDA okayed eteplirsen to treat Duchenne muscular dystrophy (DMD), a rare genetic disorder that results in muscle degeneration and premature death. Several of its top officials disagreed with the drug’s approval, questioning how beneficial it will be for patients, as Forbes, MedPage Today and others reported.

In a lengthy report Commissioner Robert Califf sent to senior FDA officials on September 16 — that was made public on September 19 — he called for the retraction of a 2013 study published in Annals of Neurology funded by the seller of eteplirsen, which showed beneficial effects of the drug in DMD patients. Califf writes in the report:

Continue reading Amid controversial Sarepta approval decision, FDA head calls for key study retraction

What if scientists funded each other?

Johan Bollen
Johan Bollen

We were struck recently by a paper in Scientometrics that proposed a unique way to fund scientists: Distribute money equally, but require that each scientist donate a portion to others – turning the federal funding system into a crowd-sourcing venture that funds people instead of projects. The proposal could save the inordinate amount of time scientists currently spend writing (and re-writing) grants, but would it actually work? First author Johan Bollen, of Indiana University, explains.

Retraction Watch: You propose something quite unique: Fund everyone equally, but ask them to give a fraction of their funding to someone else. Is the idea that scientists most respected by their peers will “earn” a higher percentage of funding, and everyone is just acting as reviewers? Continue reading What if scientists funded each other?

Journal to retract study declaring safety of asbestos roofs: Report

joehOnly a few months after publication, an environmental journal has told an activist group it plans to retract a paper about the safety of roofing products containing asbestos after facing heavy criticism.

This summer, Journal of Occupational and Environmental Hygiene (JOEH) received multiple letters asking the to retract the paper. Critics of the paper — which concluded that exposures to asbestos-containing roofing products were within safety limits — argued the article provided misleading information, grouped different materials with different asbestos exposures together, and failed to note the approving editor’s ties to the asbestos industry.

The article was published as a case study, which is considered a type of “column” by the journal, thereby bypassing its peer-review system; according to an email the journal sent to the organization Right on Canada (which a representative forwarded to Retraction Watch), this served as the basis for the journal’s decision to pull the paper.

According to the email, the journal’s editorial board decided on August 10 to retract “Airborne asbestos exposures associated with the installation and removal of roofing products” due to

Continue reading Journal to retract study declaring safety of asbestos roofs: Report

Authors retract 2016 cancer study when data don’t align with figures

cell-death-and-differentiationResearchers have retracted a 2016 cancer study, citing discrepancies between the data and images presented in the paper. 

Although the retraction notice itself contains relatively little information, we’ve obtained a letter from the last author — Jun-Li Luo of The Scripps Research Institute in Jupiter, Florida — to the editor-in-chief of Cell Death and Differentiation that says a bit more. 

According to the letter, after receiving the anonymous email, Luo conducted an investigation, contacting co-authors who contributed each of the figures in question. Although Luo writes that he has no reason to suspect fraud, the researchers were not able to provide some of the original data.

PubPeer commenters have questioned figures 1, 3, 4, 5, 6 and 7 in the study, “IKKα-mediated biogenesis of miR-196a through interaction with Drosha regulates the sensitivity of cancer cells to radiotherapy.”

In the letter, Luo tells Gerry Melino, co-editor-in-chief of the journal from the University of Leicester, UK, that figures 3D and 3E were provided by the study’s first author, Xing Fang, adding: Continue reading Authors retract 2016 cancer study when data don’t align with figures

When does “overlap” become plagiarism? Here’s what PLOS ONE decided

PLOSOne

Consider this: Fragments of a PLOS ONE paper overlap with pieces of other publications. The authors used them without credit and without quotation marks.

This sounds an awful lot like plagiarism — using PLOS‘s own standards, even. But the journal isn’t calling it plagiarism. They’ve labeled this an instance of “text overlap,” a spokesperson told us, based on the amount of material that the paper shares with others.

The last author — Carlo Croce, who has two retractions under his belt — denies that he plagiarized, and says that his university has cleared him of a plagiarism charge from an anonymous whistleblower.

PLOS fixed this case last year with a correction notice — not the common course of action for a case of confirmed plagiarism. Take a look at the notice for yourself:

Continue reading When does “overlap” become plagiarism? Here’s what PLOS ONE decided

Correction cites “unreliable” data in paper by researchers at center of Duke lawsuit

Journal of Biological ChemistryA researcher charged with embezzlement — and now the subject of a multi-million dollar lawsuit — has earned another correction, again citing “unreliable” data.

But this doesn’t appear to be a run-of-the-mill correction notice.

Firstly, it affects a paper co-authored by Erin Potts-Kant and William Foster, former Duke employees now being sued (along with Duke) for including fraudulent data in $200 million worth of federal grants. Secondly, the notice in the Journal of Biological Chemistry is four paragraphs long, and includes six figures — it would normally be considered a “mega-correction.” But lastly, even though the notice is labeled a “correction,” it’s not immediately apparent which aspects of the paper are being changed.

Here are some excerpts from the newest notice: Continue reading Correction cites “unreliable” data in paper by researchers at center of Duke lawsuit

Columbia has settled a fraud case for $9.5M. Here’s why that’s important.

John Thomas
John Thomas

This summer, Columbia University signed a settlement agreement with the U.S. government over a case filed under the False Claims Act (FCA), which enables whistleblowers to sue institutions on behalf of the government. Although this may seem like one of the many legal issues facing academic science recently, this case merits a closer look, says John R. Thomas, Jr., an attorney with Gentry Locke who represents whistleblowers in a variety of FCA cases – including a potentially landmark case against Duke University that we covered for Science. Thomas – who also authored a three-part Retraction Watch primer on how to file an FCA suit (“So You Want to Be a Whistleblower?” Part One, Part Two, Part Three) – tells us what we need to know about this latest FCA verdict.

As readers of Retraction Watch are unfortunately well aware, dishonesty in research comes in many forms. While we often focus on dishonesty in research itself, scientists and institutions may also defraud the government through a variety of administrative avenues, such as effort reporting (accounting for researcher time), improper cost accounting, and inflated facilities and administrative (F&A) costs.

We saw an example of this in July, when Continue reading Columbia has settled a fraud case for $9.5M. Here’s why that’s important.

U.S. gov’t researchers withdraw climate paper after using pseudonyms

adv-space-resClimate scientists from the U.S. Department of Agriculture have withdrawn a study they wrote under eyebrow-raising pseudonyms.

The withdrawn paper, about predicting surface temperatures of planets, appeared in Advances in Space Research in August, 2015, and is authored by Den Volokin and Lark ReLlez.

Normally, a withdrawal wouldn’t raise our eyebrows, but climate scientist Gavin Schmidt pointed out on Twitter that the authors’ names are eerily similar to another pair who have published climate papers together: Ned Nikolov and Karl Zeller. Yes, that’s correct — Den Volokin and Lark ReLlez are Ned Nikolov and Karl Zeller spelled backwards. Nikolov and Zeller are currently listed as a physical scientist and a meteorologist, respectively, at the U.S. Department of Agriculture.

The notice doesn’t state the reason for withdrawal, and Pascal Willis, editor-in-chief of Advances in Space Research from the Earth Physics Institute in Paris, France, referred us to the study’s authors for more information. Elsevier, which publishes Advances in Space Research, confirmed that the paper was retracted due to an “authorship issue” — namely, that the authors had used pseudonyms.

We used the contact information listed on the paper for “Den Volokin,” and got this response: Continue reading U.S. gov’t researchers withdraw climate paper after using pseudonyms

Do scientific manuscripts need cover letters?

James Kenar
James Kenar

How important is it to include a cover letter with a manuscript submission?

It seems that opinions differ. A 2013 article in Science Careers asked if it was a “relic;” but in a recent editorial, a journal editor reassures his readers that yes, he reads every cover letter — and yes, it’s important. (If you agree with him, let us know in our poll, below.)

In “Dear Authors: We Do Read Your Cover Letters,” James Kenar, editor of the Journal of the American Oil Chemists’ Society, insists on their importance: Continue reading Do scientific manuscripts need cover letters?

U Colorado revokes PhD of former “golden boy”

university-of-colorado-denver-300x58In a rare move, the University of Colorado has revoked the PhD of a former student in a pharmaceutical research lab, following an investigation that raised concerns about the integrity of his work.

According to The Denver Post, Rajendra Kadam’s degree has been revoked by the University of Colorado Board of Regents.

Last year, an investigation by the University of Colorado Denver into Kadam’s research recommended retracting 10 papers. As we reported at the time, the report flagged eight additional papers co-authored by Kadam whose data could not be validated, raising “concerns as to the scientific validity and integrity” of the material.

Last month, a University of Colorado Denver spokesperson told us Kadam was no longer affiliated with the university; today, Ken McConnellogue, the vice president for communication, confirmed that his degree has now been revoked entirely.

McConnellogue acknowledged that it was a strong move: Continue reading U Colorado revokes PhD of former “golden boy”